News for X4 Pharmaceuticals, Inc. (XFOR)

Published at

Mar 25, 2025 8:02 PM

by seekingalpha.com

positive

positive

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ETCompany ParticipantsDaniel Ferry - IR, LifeSci...

XFOR

Read more →
Published at

Mar 25, 2025 2:11 PM

by gurufocus.com

positive

positive

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings: Revenue Surpasses Estimates at $1.4M, EPS Misses at -$0.20

Revenue: Reported net product revenue of $1.4 million for Q4 2024, surpassing the estimated revenue of $1.04 million.Earnings Per Share (EPS): Recorded a net l

XFOR

Read more →
Published at

Mar 25, 2025 1:00 PM

by gurufocus.com

positive

positive

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated i

XFOR

Read more →
Published at

Mar 25, 2025 11:11 AM

by manilatimes.net

positive

positive

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

**media[575631]**

XFOR

Read more →
Published at

Mar 24, 2025 6:56 PM

by seekingalpha.com

negative

negative

X4 Pharmaceuticals Q4 2024 Earnings Preview (NASDAQ:XFOR)

X4 Pharmaceuticals (XFOR) Q4 earnings release on Mar 25: EPS estimate at -$0.16 & revenue at $1.06M.

XFOR

Read more →
Published at

Mar 24, 2025 2:05 PM

by gurufocus.com

neutral

neutral

X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For

X4 Pharmaceuticals Inc (XFOR) is set to release its Q4 2024 earnings on Mar 25, 2025. The consensus estimate for Q4 2024 revenue is $1.04 million, and the earni

XFOR

Read more →
Published at

Feb 3, 2025 10:09 PM

by manilatimes.net

positive

positive

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

**media[531114]**

XFOR

Read more →
Published at

Jan 31, 2025 7:03 PM

by gurufocus.com

positive

positive

Vanguard Group Inc Reduces Stake in X4 Pharmaceuticals Inc

On December 31, 2024, Vanguard Group Inc made a strategic decision to reduce its holdings in X4 Pharmaceuticals Inc (XFOR) by 239,827 shares. This transaction r

XFOR NVDAD.BA NVDAC.BA NVDA.MI MSFTCL.SN APC.DE AMZNCL.SN AMZN.SN AMZN.MX AMZN AMZ.DE AAPLCL.SN AAPL.SN AAPL.MX AAPL

Read more →
Published at

Jan 24, 2025 2:08 PM

by manilatimes.net

positive

positive

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

**media[523363]**

XFOR

Read more →
Published at

Jan 13, 2025 1:46 PM

by manilatimes.net

positive

positive

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

**media[513442]**

XFOR

Read more →
Published at

Dec 4, 2024 2:20 PM

by investing.com

positive

positive

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition By Investing.com

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

XFOR

Read more →
Published at

Dec 4, 2024 2:12 PM

by manilatimes.net

positive

positive

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

**media[483208]**

XFOR

Read more →
Published at

Dec 3, 2024 11:00 PM

by gurufocus.com

positive

positive

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals ( XFOR), a company driven to improve the lives of people with rare diseases of the immune system,

XFOR

Read more →
Published at

Dec 3, 2024 10:26 PM

by manilatimes.net

positive

positive

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

**media[482601]**

XFOR

Read more →
Published at

Nov 14, 2024 3:33 AM

by seekingalpha.com

neutral

neutral

X4 Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation (NASDAQ:XFOR)

The following slide deck was published by X4 Pharmaceuticals, Inc.

XFOR

Read more →
Published at

Nov 14, 2024 3:31 AM

by seekingalpha.com

positive

positive

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ETCompany ParticipantsDaniel Ferry - IR, LifeSci...

XFOR

Read more →
Published at

Oct 9, 2024 9:39 PM

by gurufocus.com

positive

positive

Q2 2024 X4 Pharmaceuticals Inc Earnings Call Transcript

Aug 08, 2024 / 12:30PM GMTOperator Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference Call. (Operator Instruction

XFOR

Read more →
Published at

Oct 8, 2024 10:48 PM

by investing.com

positive

positive

X4 Pharmaceuticals CFO sells shares worth over $126k By Investing.com

X4 Pharmaceuticals CFO sells shares worth over $126k

XFOR

Read more →
Published at

Mar 7, 2024 1:01 PM

by marketscreener.com

mixed

mixed

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors . Ms. Lurker is a seasoned...

MNKKQ MNK EYPT BRM.DE BMYB34.SA BMY.MX BMY.BA BMY ALKS 6099.T XFOR PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA 0K9E.L AQST

Read more →
Published at

Dec 11, 2023 7:12 PM

by benzinga.com

mixed

mixed

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday’s Mid-Day Session - African Agriculture Hldgs (NASDAQ:AAGR), Apellis Pharmaceuticals (NASDAQ:APLS)

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

VAPO SHAK.MX SHAK ONTXW ONTX NXTP MPSYF MOR.DE MOR LIN ISUN IPDN IOM.V IKT DOGZ COMM CI BPMC BMEA BLUE.MX BLUE ARHHD ARHH 0L5R.L 0HOJ.L 0HOH.L ZLABN.MX ZLAB XFOR VERU TRKA MTN MARA.MX MARA MACY34.SA M.MX M&MFIN.NS M&M.NS M&M.BO M KROS KOD.MX KOD HUM.MX HUM GIL.TO GIL EFTR DISH.MX DISH D1IS34.SA CYTO CLSK APLS 9688.HK 2389.T 0JXD.L 0J6Z.L 0IBG.L BTBTN.MX BTBT

Read more →